Contego Medical has enrolled the first subject in the PERFORMANCE III study, which is designed to further assess the effectiveness and safety of the Neuroguard IEPDirect System.

This multicentre and prospective trial is a follow-on to the fully enrolled PERFORMANCE II study of the carotid stent system.

The PERFORMANCE II trial has been conducted to assess the same stent placed through percutaneous transfemoral or transradial access.

Both trials are being carried out under an investigational device exemption (IDE) through the US Food and Drug Administration (FDA). 

Both the Neuroguard IEP and Neuroguard IEP Direct Systems utilise the company’s IEP (integrated embolic protection) technology, which comes with a micro-filter integrated into the delivery catheter.

The micro-filter helps capture the micro-emboli, enabling physicians to better treat patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Neuroguard IEP Direct System features a new single-access-point blood flow reversal system that facilitates direct transcarotid access.

For minimising catheter exchanges and enhancing treatment efficiency, the Neuroguard system is designed as a three-in-one catheter with a stent, balloon and micro-filter.

In addition, the device leverages FlexRingstent technology, offering properties of both open and closed cell stents.

Contego Medical CEO Dr Ravish Sachar said: “At Contego, we’re driven to improve patient outcomes and will continue to collect robust clinical data to build upon the unprecedented stroke protection results already demonstrated with our IEP platform technology in the PALADIN and PERFORMANCE I studies.”

The company’s product portfolio includes the FDA-approved PaladinIEP carotid PTA balloon and filter system and the Vanguard IEPperipheral balloon angioplasty and filter system, as well as Excipio SV and LV thrombectomy devices.